|

(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Institute of Mental Health (NIMH)1

Indications

  • Behavioral Symptoms1
  • Physiological Effects of Drugs1
  • Excitatory Amino Acid Agents1
  • Neurotransmitter Agents1
  • Ketamine1

Bethesda, Maryland1 trial

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.